The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Open accessAbstract
BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC. In this trial, 602 patients with well-preserved liver function (>95% Child-Pugh A) were randomized to receive either sorafenib 400mg or matching placebo orally b.i.d. on a continuous basis. Because HCC is a heterogeneous disease, baseline patient characteristics may affect individual responses to treatment. In a comprehensive series of exploratory subgroup analyses, data from the SHARP trial were analyzed to discern if baseline patient characteristics influenced the efficacy and safety of sorafenib. METHODS: Five subgroup domains were assessed: disease etiology, tumor burden, performance status, tumor stage, and prior therapy. Overall survival (OS), time to progression (TTP), disease control rate (DCR), and safety were assessed for subgroups within each domain. RESULTS: Subgroup analyses showed that sorafenib consistently improved median OS compared with placebo, as reflected by hazard ratios (HRs) of 0.50-0.85, similar to the complete cohort (HR=0.69). Sorafenib also consistently improved median TTP (HR, 0.40-0.64), except in HBV-positive patients (HR, 1.03), and DCR. Results are limited by small patient numbers in some subsets. The most common grade 3/4 adverse events included diarrhea, hand-foot skin reaction, and fatigue; the incidence of which did not differ appreciably among subgroups. CONCLUSIONS: These exploratory subgroup analyses showed that sorafenib consistently improved median OS and DCR compared with placebo in patients with advanced HCC, irrespective of disease etiology, baseline tumor burden, performance status, tumor stage, and prior therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationManagement of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Self-citationWilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Self-citationHepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Cited by
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
Self-citationLlovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Self-citationEvidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
Bruix, J., Reig, M., & Sherman, M. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.041 · Cited by 1,694
Self-citationChallenges in liver cancer and possible treatment approaches
Anwanwan, D., Singh, S. K., Singh, S., Saikam, V., & Singh, R. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188314 · Cited by 1,481
Hepatocellular carcinoma: a review
Balogh, J., Victor, D., Asham, E. H., Burroughs, S. G., Boktour, M., Saharia, A., Li, X., Ghobrial, M., & Monsour, H. (2016) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s61146 · Cited by 1,185
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120
Self-citationSingal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
Self-citationVilgrain, V., Pereira, H., Assenat, E., Guiu, B., Ilonca, A. D., Pageaux, G.-P., Sibert, A., Bouattour, M., Lebtahi, R., Allaham, W., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30683-6 · Cited by 834
Self-citationCheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777
Targeted therapy for hepatocellular carcinoma
Huang, A., Yang, X.-R., Chung, W.-Y., Dennison, A. R., & Zhou, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00264-x · Cited by 739
Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer · doi:10.1159/000514174 · Cited by 678
Lencioni, R., Llovet, J. M., Han, G., Tak, W. Y., Yang, J., Guglielmi, A., Paik, S. W., Reig, M., Kim, D. Y., Chau, G.-Y., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.012 · Cited by 694
Self-citationGarin, E., Tselikas, L., Guiu, B., Chalaye, J., Edeline, J., de Baere, T., Assenat, E., Tacher, V., Robert, C., Terroir-Cassou-Mounat, M., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30290-9 · Cited by 630
Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Llovet, J. M., Villanueva, A., Lachenmayer, A., & Finn, R. S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.103 · Cited by 621
Self-citationBruix, J., Cheng, A.-L., Meinhardt, G., Nakajima, K., De Sanctis, Y., & Llovet, J. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.026 · Cited by 562
Self-citationSantoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J. L., Van Vlierberghe, H., Trojan, J., Kolligs, F. T., Weiss, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70490-4 · Cited by 554
Self-citationKokudo, N., Takemura, N., Hasegawa, K., Takayama, T., Kubo, S., Shimada, M., Nagano, H., Hatano, E., Izumi, N., Kaneko, S., et al. (2019) · Hepatology Research · doi:10.1111/hepr.13411 · Cited by 521
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Kelley, R. K., El-Khoueiry, A., Reeves, H. L., Wang, X. W., Gores, G. J., & Villanueva, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00357-2 · Cited by 498
Self-citationTreatment of intermediate-stage hepatocellular carcinoma
Forner, A., Gilabert, M., Bruix, J., & Raoul, J.-L. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.122 · Cited by 466
Self-citationHepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers
Wang, Y., & Deng, B. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10084-4 · Cited by 415
Dietary Natural Products for Prevention and Treatment of Liver Cancer
Zhou, Y., Li, Y., Zhou, T., Zheng, J., Li, S., & Li, H.-B. (2016) · Nutrients · doi:10.3390/nu8030156 · Cited by 411
Korean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Self-citationNon-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets
Klingenberg, M., Matsuda, A., Diederichs, S., & Patel, T. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.009 · Cited by 354
Rimassa, L., Assenat, E., Peck-Radosavljevic, M., Pracht, M., Zagonel, V., Mathurin, P., Rota Caremoli, E., Porta, C., Daniele, B., Bolondi, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30146-3 · Cited by 351
Self-citation2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Transarterial chemoembolization: Modalities, indication, and patient selection
Sieghart, W., Hucke, F., & Peck-Radosavljevic, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.010 · Cited by 336
Treatment of Hepatocellular Carcinoma: A Systematic Review
Lin, S., Hoffmann, K., & Schemmer, P. (2012) · Liver Cancer · doi:10.1159/000343828 · Cited by 334
Kudo, M., Han, K.-H., Ye, S.-L., Zhou, J., Huang, Y.-H., Lin, S.-M., Wang, C.-K., Ikeda, M., Chan, S. L., Choo, S. P., et al. (2020) · Liver Cancer · doi:10.1159/000507370 · Cited by 314
Sorafenib: A Review in Hepatocellular Carcinoma
Keating, G. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0484-7 · Cited by 308
Lyu, N., Kong, Y., Mu, L., Lin, Y., Li, J., Liu, Y., Zhang, Z., Zheng, L., Deng, H., Li, S., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.02.008 · Cited by 281
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options
Foerster, F., Gairing, S. J., Müller, L., & Galle, P. R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.007 · Cited by 280
Self-citationGuidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Abrams, T. A., Alberts, S. R., Anaya, D. A., Anders, R., Are, C., Brown, D., Chang, D. T., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0019 · Cited by 269
Serper, M., Taddei, T. H., Mehta, R., D’Addeo, K., Dai, F., Aytaman, A., Baytarian, M., Fox, R., Hunt, K., Goldberg, D. S., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.040 · Cited by 265
Comparison of hepatocellular carcinoma in Eastern versus Western populations
Choo, S. P., Tan, W. L., Goh, B. K. P., Tai, W. M., & Zhu, A. X. (2016) · Cancer · doi:10.1002/cncr.30237 · Cited by 264
Wang, Q., Xia, D., Bai, W., Wang, E., Sun, J., Huang, M., Mu, W., Yin, G., Li, H., Zhao, H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.013 · Cited by 261
Meyer, T., Galani, S., Lopes, A., & Vogel, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.012 · Cited by 82
Ding, Z., Dong, Z., Chen, Z., Hong, J., Yan, L., Li, H., Yao, S., Yan, Y., Yang, Y., Yang, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733530 · Cited by 47
Yu, Z., Feng, H., Zhuo, Y., Li, M., Zhu, X., Huang, L., Zhang, X., Zhou, Z., Zheng, C., Jiang, Y., et al. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00546-0 · Cited by 27
Cheng, C.-C., Chao, W.-T., Liao, C.-C., Tseng, Y.-H., Lai, Y.-C. C., Lai, Y.-S., Hsu, Y.-H., & Liu, Y.-H. (2018) · Cell Adhesion & Migration · doi:10.1080/19336918.2017.1288789 · Cited by 21
“HCC is often diagnosed at an advanced stage and unable to treat with radical operations.16 Systemic therapy targeting cancer cells is an alternative option for the management of HCC. Sorafenib is a multi-targeting tyrosine kinase inhibitor that blocks the activity of Raf serine/threonine kinase isoforms in consequence…”
BackgroundInfluentialDu, Q., Yuan, J., & Ren, Z. (2024) · Liver Cancer · doi:10.1159/000534446 · Cited by 20
Metadata
- Authors
- Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., Porta, C., Gerken, G., Marrero, J. A., Nadel, A., Shan, M., Moscovici, M., Voliotis, D., & Llovet, J. M.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 57
- Issue
- 4
- Pages
- 821-829
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2058887247
- Cited by
- 822
- References
- 42
- FWCI
- 33.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.